← SynDRA
PROBUCOL
SynDRA canonical compound SYN0001138 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · OTC |
|---|
| Primary target(s) | ABCA1 |
|---|
| Mechanism of action | Atherogenesis inhibitor |
|---|
| Indication | coronary artery disease (CAD) |
|---|
| Disease area | cardiology |
|---|
All known targets
- ABCA1
- ABCB11
- ALOX15
- CES1
- HPN
- KCNH2
- SIRT5
Mechanisms of action (all sources)
- Atherogenesis inhibitor
- ABCA1 INHIBITOR
- ATP-binding cassette sub-family A member 1 inhibitor
- ABCA1 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ACHE
- GCGR
- NR3C1
- NPY2R
- NPY1R
- MMP9
- MMP1
- MLNR
- MC5R
- MC4R
- MC3R
- MAPT
- MAPK3
- MAPK14
- MAPK1
- MAOA
- LCK
- HTR6
- HTR3A
- HTR2C
- HTR2B
- HTR2A
- HTR1A
- HRH3
- HRH2
- HRH1
- HMGCR
- HDAC6
- GIPR
- NTSR1
- OPRD1
- OPRK1
- SLC6A2
- VCAM1
- USP1
- TDP1
- TBXAS1
- TBXA2R
- TACR2
- TACR1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Anticholesteremic Agents
- Antimetabolites
- Antioxidants
- Hypolipidemic Agents
- Lipid Regulating Agents
- Protective Agents
ATC classes
- C10A · LIPID MODIFYING AGENTS, PLAIN
Cross-references
Synonyms
- LORELCO
- biphenabid
- bisphenabid
- phenbutol
- lorelco
- DH-581
- NSC-652160
- NSC-86225
- Bisbid
- Lorelco
- Lurselle
- Sinlestal
- Biphenabid
- Bisphenabid
- Lesterol
- Lursell
- Panavir
- Probucolum
- Superlipid
- Almirall Brand of Probucol
- Aventis Brand of Probucol
- Hoechst Brand of Probucol
- DH581
- DE-3872
- LORELCO (TN)
- Probucolum [INN-Latin]
- ZERO/001429
- Probucol (JAN/USP/INN)
- Probucol [USAN:BAN:INN:JAN]
- 4,4'-(Isopropylidenedithio)bis(2, 6-di-tert-butylphenol)
- 4,4'-(Isopropylidenedithio)bis[2, 6-di-tert-butylphenol]
- DH 581
- P3CTH044XJ
- NSC 86225
- NSC 652160
- CHEBI:8427
- DTXCID0025440
- probucolo
Look up PROBUCOL in the interactive SynDRA portal →